Organization | Hisamitsu Pharmaceutical Co., Inc.

Hisamitsu Pharmaceutical Co., Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Tosu Japan (1847)

Organization Overview

First Clinical Trial

2007

NCT00792727

First Marketed Drug

2008

menthol (Salonpas)

First NDA Approval

2008

menthol (Salonpas)

Last Known Activity

2019

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Hisamitsu | HISAMITSU | Hisamitsu Farmaceutica do Brasil Ltda | HISAMITSU PHARM CO

Active Ingredients

Marketed Drugs (7)

Key: Hisamitsu Pharmaceutical Co., Inc. (6) Acquired (1)

asenapine (saphris) (2019)

dextroamphetamine (Dexedrine) (2022)

estradiol (progynon depot) (2012)

fentanyl (Innovar) (2009)

lidocaine (xylocaine) (2020)

menthol (Salonpas) (2008 NDA)

methyl salicylate (2008 NDA)

Drugs in Phase 4 Trials (1)

Key: Hisamitsu Pharmaceutical Co., Inc. (0) Acquired (1)

methylphenidate (ritalin) (8 trials)

Drugs in Phase 3 Trials (6)

Key: Hisamitsu Pharmaceutical Co., Inc. (2) Acquired (4)

asenapine (saphris) (1 trial)

diclofenac (voltaren) (2 trials)

ketoprofen (orudis) (5 trials)

lithium (lithonate) (1 trial)

paroxetine (paxil) (4 trials)

salicylic acid (1 trial)

Drugs in Phase 2 Trials (2)

Key: Hisamitsu Pharmaceutical Co., Inc. (1) Acquired (1)

amphetamine (Adderall) (2 trials)

htu-520 (1 trial)

Drugs in Phase 1 Trials (2)

Key: Hisamitsu Pharmaceutical Co., Inc. (0) Acquired (2)

acetazolamide (diamox) (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

Indications

Approved Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Ankle Injuries (Phase 3)

Contusions (Phase 3)

Myalgia (Phase 3)

Onychomycosis (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Shoulder Pain (Phase 3)

Sprains and Strains (Phase 3)

Tendinopathy (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 27
# of Trial APIs: 11